IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
KYTX News
Archived Headlines
- Autoimmune disease biotech Kyverna Therapeutics ups deal size by 49% ahead of $297 million IPO 02/06/24
- US IPO Week Ahead: Real estate, groceries, insurance, and more come to the IPO market 02/02/24
- Autoimmune disease biotech Kyverna Therapeutics sets terms for $200 million IPO 02/01/24
- US IPO Weekly Recap: Kaspi.kz completes billion-dollar US listing as more big names join the pipeline 01/19/24
- Autoimmune disease biotech Kyverna Therapeutics files for a $100 million IPO 01/16/24
Updated: Renaissance Capital's 1Q 2024 US IPO Market Review
US IPO Market's Green Shoots Take Root In the first quarter of 2024, the IPO market's green shoots grew further, with 30 IPOs raising a combined $7.8 billion. While deal count was in line with the 1Q23, proceeds more than tripled, thanks to the continued return of larger offerings. Fifteen US IPOs raised $100 million...read more
Renaissance Capital's February IPO Market Update
In February, 10 IPOs raised a combined $2.0 billion, led by early debuts from a handful of $100+ million offerings. Deal flow was led by healthcare and senior facilities provider American Healthcare REIT (AHR) and Mexican discount grocer BBB Foods (TBBB), which together accounted for nearly two-thirds of the month's proceeds raised. Activity...read more
US IPO Weekly Recap: Autoimmune biotech Kyverna Therapeutics gains 37% in a 6 IPO week
Six IPOs priced this past week, joined by two blank check companies. One larger deal did not get done: Fortegra (TFG) pulled its $297 million offering ahead of its expected pricing. The specialty insurer had previously attempted to go...read more
Autoimmune disease biotech Kyverna Therapeutics prices IPO at $22, above the revised range
Kyverna Therapeutics, a Phase 1 biotech developing cell therapies for autoimmune diseases, raised $319 million by offering 14.5 million shares at $22, above the upwardly revised range of $20 to $21. The company originally planned to offer 11.1 million shares at $17 to $19 before revising the terms on Tuesday. Kyverna Therapeutics is focused on developing cell therapies for patients...read more